{"filings":[{"id":612080,"accession_number":"0001193125-26-237207","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-22T21:28:16+00:00","items":["3.01","5.02"],"status":"ready","headline":"Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.","Directors Michael Raab and Christine Pellizzari resigned, causing non-compliance with majority independence and committee rules.","Company not eligible for standard cure period due to multiple vacancies; must submit plan for board compliance within 45 days.","Both deficiencies have no immediate listing effect but risk delisting if plans rejected or compliance not achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":"2026-05-22","daily_digest_url":"/daily/2026-05-22","daily_digest_rank":1},{"id":611637,"accession_number":"0001193125-26-237150","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-22T21:05:53+00:00","items":["5.02"],"status":"ready","headline":"Three directors resign from Tempest Therapeutics board effective May 22, 2026","event_type":"leadership","confidence":"high","bullets":["Stephen Brady, Michael Raab, and Christine Pellizzari resigned from the Tempest board on May 22, 2026.","Resignations not due to any disagreement with the company on operations, policies, or practices.","Separation agreements waive accrued unpaid director retainer fees; stock options and indemnification remain.","Board size reduced by three members; no replacements announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443443,"accession_number":"0001193125-26-224156","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-14T20:28:56+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials","event_type":"earnings","confidence":"high","bullets":["Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.","TPST-2003 showed 100% complete response in 15 CAR-T-naïve evaluable patients across two trials; no Grade ≥3 CRS/ICANS.","Selected Cincinnati Children's AGCTC as lead manufacturing partner; lentiviral vector received for TPST-2003.","Appointed Andrew Fang, Ph.D., as Head of Business Development to lead partnerships and licensing.","Completed asset acquisition of dual-targeting CAR-T assets from Factor Bioscience and Erigen; $6M private placement closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93558,"accession_number":"0001193125-26-207601","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003","event_type":"other_material","confidence":"high","bullets":["100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.","Favorable safety: no Grade >3 CRS or ICANS observed; 44 patients dosed across three studies to date.","Median progression-free survival of 23.1 months in rrMM patients, including those with extramedullary disease.","All 10 evaluable REDEEM-1 patients achieved CR per IMWG criteria; one prior BCMA CAR-T patient did not respond.","Company plans to meet with FDA later this year to discuss initiating a U.S. registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105281,"accession_number":"0001193125-26-130480","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.","Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.","Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.","TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.","Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105280,"accession_number":"0001193125-26-118618","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tempest Therapeutics raises ~$2M in private placement of stock and warrants","event_type":"other_material","confidence":"high","bullets":["Raised ~$2M gross from private placement of 462,964 shares + pre-funded warrants at $2.16 per unit.","Issued Series A (5-yr) and Series B (24-mo) warrants exercisable at $2.16; exercisable upon stockholder approval.","Proceeds to be used for working capital; closing expected March 23, 2026.","Registration rights agreement requires filing resale registration within 15 days.","H.C. Wainwright served as placement agent; fees of 6% (institutional) and 3% (strategic)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105279,"accession_number":"0001193125-26-068614","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026","event_type":"other_material","confidence":"high","bullets":["100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.","Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.","Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.","Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.","Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105278,"accession_number":"0001193125-26-045543","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tempest Therapeutics files updated corporate presentation; no specific new data disclosed in filing.","event_type":"other_material","confidence":"low","bullets":["Company posted February 2026 investor presentation on its website.","Presentation title: 'Accelerating the Development of Advanced Therapies for Cancer Patients'.","No financial or clinical trial results were included in the 8-K filing.","Investors should refer to the full presentation on the company's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105277,"accession_number":"0001193125-26-041190","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","2.01","3.02","5.01","5.02","9.01"],"status":"ready","headline":"Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing","event_type":"m_and_a","confidence":"high","bullets":["Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.","Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.","Geoff Nichol resigned from Board; Michael Raab stepped down as Chair; Stephen Brady appointed Chair.","Stephen Brady resigned as CEO; Matt Angel appointed President, CEO and Class I director; $650k salary, 50% bonus, 269,621 option.","Issued 6.78M warrants at $18.48/exercise, expiring Feb 3 2031, to existing shareholders as a dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105276,"accession_number":"0001193125-26-027203","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["3.03","5.02","5.07"],"status":"ready","headline":"Tempest shareholders approve share issuance for asset purchase and extend rights plan","event_type":"other_material","confidence":"high","bullets":["Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.","Stockholders extended limited duration rights plan to October 10, 2026.","Amendment to 2023 Equity Incentive Plan approved, increasing share reserve by 1,410,000 shares.","Geoff Nichol elected Class I director with 1,003,845 votes for; broker non-votes 1,075,928.","Advisory say-on-pay approved with 816,856 votes for, 428,524 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105275,"accession_number":"0001193125-26-008938","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Tempest Therapeutics gets Nasdaq notice for missing annual meeting; meeting set for Jan 27, 2026","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Jan 8, 2026 for failing to hold annual meeting within 12 months of fiscal year end Dec 31, 2024.","Company has 45 calendar days (until Feb 23, 2026) to regain compliance or submit a plan; Nasdaq may grant exception until June 29, 2026.","Annual meeting already scheduled for Jan 27, 2026; upon holding it, compliance will be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121542,"accession_number":"0001193125-25-298604","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Tempest raises $4.25M upfront in registered direct offering; warrants add up to $4.1M","event_type":"other_material","confidence":"high","bullets":["1,172,414 shares (or equivalents) sold at $3.625/share in registered direct offering for ~$4.25M gross.","Concurrent private placement of short-term warrants to buy 1,172,414 shares at $3.50, exercisable for 18 months.","Warrants could yield additional ~$4.1M proceeds if fully exercised on a cash basis, but no guarantee.","Net proceeds used for working capital and general corporate purposes; H.C. Wainwright placement agent with 6% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121541,"accession_number":"0001193125-25-287163","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued","event_type":"m_and_a","confidence":"high","bullets":["Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.","Post-closing, existing TPST holders own ~35%; Erigen equityholders (Matt Angel and Lotus Capital) own ~38% and ~27% on fully diluted basis.","Matt Angel appointed President & CEO; Stephen Brady becomes Chairman; Geoff Nichol resigns from board, effective at closing.","Each TPST share to receive one warrant exercisable at $18.48 per share, valid for 5 years from issue date.","Closing requires stockholder approval, Angel's appointment, and a minimum $5M pre-closing financing; expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121540,"accession_number":"0001193125-25-265937","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.","Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.","R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.","Company continues strategic alternatives process to maximize stockholder value.","Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138211,"accession_number":"0000950170-25-106544","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.","Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.","R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.","Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.","Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155656,"accession_number":"0001193125-25-139899","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Tempest Therapeutics raises ~$4.6M gross in registered direct offering of stock and prefunded warrants","event_type":"other_material","confidence":"high","bullets":["Issued 405,000 shares at $6.25 each and prefunded warrants for 334,000 shares at $6.249 each.","Net proceeds estimated at ~$4.1M after placement agent fees and expenses.","Proceeds to support strategic alternative process and working capital; cash runway into Q2 2026.","Placement agent H.C. Wainwright receives 6.0% cash fee on gross proceeds.","Prefunded warrants exercisable at $0.001 per share, with 4.99% beneficial ownership limitation (holder may elect up to 9.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155655,"accession_number":"0001193125-25-138802","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest Therapeutics suspends ATM prospectus; Sales Agreement remains in effect","event_type":"other_material","confidence":"high","bullets":["Delivered notice to Jefferies to terminate ATM prospectus dated Feb 6, 2025.","No sales of common stock under Sales Agreement until new prospectus filed.","Underlying Open Market Sale Agreement with Jefferies remains in full force.","Company retains ability to resume ATM sales after filing new prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155654,"accession_number":"0001193125-25-137041","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration","event_type":"leadership","confidence":"high","bullets":["CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.","Consulting agreements are one-year, hourly compensation; executives retain their roles and responsibilities.","Separation agreements provide full acceleration of all outstanding equity awards, vested immediately on June 5, 2025.","Extended post-Transition exercise period to earlier of Change of Control or 180 days after separation.","Transition part of previously announced process to explore strategic alternatives and extend capital resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155653,"accession_number":"0000950170-25-070416","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.","Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.","Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.","FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.","TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155652,"accession_number":"0001193125-25-098817","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempest Therapeutics regains Nasdaq minimum bid price compliance","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).","Rule requires minimum bid price of $1.00 per share for continued listing.","Company had previously been notified of deficiency; now resolved.","No other regulatory or operational updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155651,"accession_number":"0001193125-25-085773","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.","Estimated $1.5M in cash severance and benefit costs, mostly in Q2 2025.","Key affected employees to transition to consulting agreements.","Company initiated process to explore strategic alternatives to extend capital resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155650,"accession_number":"0001193125-25-076938","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee","event_type":"other_material","confidence":"high","bullets":["Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.","Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.","Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.","TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.","Company cites unavailable capital markets as reason to seek a strategic partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155649,"accession_number":"0001193125-25-073987","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Tempest Therapeutics announces 1-for-13 reverse stock split effective April 8, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:13 ratio, effective 5:00 p.m. ET on April 8, 2025.","Pre-split shares outstanding: 45,764,184; post-split approx. 3,520,321 shares.","No fractional shares; cash payments in lieu of fractional shares.","Trading on Nasdaq Capital Market on split-adjusted basis from April 9, 2025.","Proportional adjustments to warrants/options exercise prices and shares reserved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174141,"accession_number":"0000950170-25-046055","cik":1544227,"company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations","event_type":"earnings","confidence":"high","bullets":["Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.","Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.","Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.","Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.","FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}